Exicorilant
CORT125281-601
Phase 2 small_molecule terminated
Quick answer
Exicorilant for Metastatic Castration-Resistant Prostate Cancer is a Phase 2 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CORCEPT THERAPEUTICS INC
- Indication
- Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated